Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OBT700R
- Development stage
- Preclinical
- Lead developer
- Oxford BioTherapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
OBT700R is a monoclonal antibody (mAb) currently in pre-clinical development by Oxford BioTherapeutics for the treatment of solid tumours. The drug was identified through the company's proprietary OGAP® (Oxford Genome Anatomy Project) database, which is designed to identify novel, disease-specific targets for cancer therapy. While the specific biological target of OBT700R remains undisclosed, the program is part of a partnered development strategy. Additionally, OBT700R serves as the targeting component for a related bispecific program, OBT700/PDL1, which combines the OBT700 targeting arm with a PD-L1 inhibitor to enhance anti-tumor immune responses.
Beyond the preview
Go deeper on OBT700R.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OBT700R.